Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Christelle Lévy"'
Autor:
Mylène Duivon, Justine Lequesne, Antonio Di Meglio, Caroline Pradon, Ines Vaz-Luis, Anne-Laure Martin, Sibille Everhard, Sophie Broutin, Olivier Rigal, Chayma Bousrih, Christelle Lévy, Florence Lerebours, Marie Lange, Florence Joly
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer
Externí odkaz:
https://doaj.org/article/89577b2bd38749a3990b4d7af210ddbf
Autor:
Thierry Petit, Nawale Hajjaji, Eric‐Charles Antoine, Marc‐Antoine Benderra, Michel Gozy, Cyril Foa, Jean‐Loup Mouysset, Julien Grenier, Mireille Mousseau, Audrey Mailliez, Mahasti Saghatchian, Emma Lachaier, Isabelle Desmoulins, Audrey Hennequin, Patricia Maes, Delphine Loirat, Francesco Ricci, Véronique Diéras, Dominique Berton, Florence Lai Tiong, Luis Teixeira, Nadine Dohollou, Christelle Lévy, Thomas Bachelot, Jean‐Yves Pierga
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial which demonstrated its efficacy and safety in HER2‐positive meta
Externí odkaz:
https://doaj.org/article/ff9bee9264c24081805649cfff9439d4
Autor:
Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot, Doriane Richard, Nasrin Sarafan-Vasseur, Frédéric Di Fiore
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospec
Externí odkaz:
https://doaj.org/article/3c56554d5803431f9169612066341163
Autor:
Mylène Duivon, Joy Perrier, Florence Joly, Idlir Licaj, Jean-Michel Grellard, Bénédicte Clarisse, Christelle Lévy, Philippe Fleury, Sophie Madeleine, Nicolas Lefèvre, Géraldine Rauchs, Grégory Lecouvey, Florence Fraisse, Fausto Viader, Francis Eustache, Béatrice Desgranges, Bénédicte Giffard
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Breast cancer (BC) is the most frequent cancer in women with more than 70% of BC patients being treated with hormonal therapy (HT). Among these patients, some report difficulties in remembering what they are supposed to do at the
Externí odkaz:
https://doaj.org/article/c9f659aed4854b4297b2f497f63c82ca
Autor:
Junien Sirieix, Julien Fraisse, Simone Mathoulin-Pelissier, Marianne Leheurteur, Laurence Vanlemmens, Christelle Jouannaud, Véronique Diéras, Christelle Lévy, Mony Ung, Marie-Ange Mouret-Reynier, Thierry Petit, Bruno Coudert, Etienne Brain, Barbara Pistilli, Jean-Marc Ferrero, Anthony Goncalves, Lionel Uwer, Anne Patsouris, Olivier Tredan, Coralie Courtinard, Sophie Gourgou, Jean-Sébastien Frénel
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background and Aims: Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, manage
Externí odkaz:
https://doaj.org/article/90cce4c7f9c846058185ea6591dcfcce
Autor:
Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, Thomas Bachelot, Patrick Soulié, Christelle Jouannaud, Hugues Bourgeois, Thierry Petit, Isabelle Tennevet, David Assouline, Marie-Christine Mathieu, Jean-Philippe Jacquin, Sandrine Lavau-Denes, Ariane Darut-Jouve, Jean-Marc Ferrero, Carole Tarpin, Christelle Lévy, Valérie Delecroix, Véronique Trillet-Lenoir, Oana Cojocarasu, Jérôme Meunier, Jean-Yves Pierga, Cécile Agostini, Pierre Kerbrat, Céline Faure-Mercier, Hélène Blanché, Mourad Sahbatou, Anne Boland, Delphine Bacq, Céline Besse, Fabien Calvo, Alexia Renaud, Jean-François Deleuze, Iris Pauporté, Gilles Thomas, David G. Cox
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-5 (2017)
Genetics: heredity does not explain HER2 expression A large gene-finding study failed to identify any hereditary factors linked to HER2 expression among women with breast cancer. A team in France led by Xavier Pivot from the University Hospital Cente
Externí odkaz:
https://doaj.org/article/7754f161934e43488fc3e34446964363
Autor:
Garazi Ruiz de Azua, Isabelle Kousignian, Ines Vaz‐Luis, Antonio Di Meglio, Elsa Caumette, Julie Havas, Elise Martin, Anne‐Laure Martin, Ophelie Querel, Laurence Vanlemmens, Barbara Pistilli, Charles Coutant, Paul Henri Cottu, Asma Dhaini Merimeche, Florence Lerebours, Olivier Tredan, Christelle Jouannaud, Christelle Levy, Agnes Dumas, Gwenn Menvielle
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19091-19101 (2023)
Abstract Purpose This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods We used data from the prospective French cohort, CANTO. We included 1811 stage I–III BCS who were 50 (OR = 0.59; 95%CI = 0.43–0.82),
Externí odkaz:
https://doaj.org/article/caaf22a6096241ad9f5aa1968c778c76
Autor:
François Gernier, Jean-Michel Grellard, Charlotte Dupont, Hervé Castel, Marie Fernette, François Lahaye, Rose-Marie Charles, Tiphaine Leroux, Céline Ory, Audrey Faveyrial, Adeline Morel, George Emile, Christelle Levy, Carine Segura, Djelila Allouache, Alison Johnson, Julien Geffrelot, Katharina Gunzer, Anaïs Lelaidier, Gilles Girault, Coraline Dubot-poitelon, Chankannira San, Justine Lequesne, Bénédicte Clarisse
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Non-metastatic breast cancer treatment is mainly based on surgery, with or without chemotherapy, radiotherapy and/or hormone therapy. To reduce the risk of hormone receptor positive (HR+) disease recurrence, hormone therapy is pre
Externí odkaz:
https://doaj.org/article/26a7a9b19d2643669b2a86b963b0dcee
Autor:
François Cherifi, Angélique Da Silva, Alison Johnson, Cécile Blanc-Fournier, Olivia Abramovici, Antonin Broyelle, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Clémence Boscher, Coraline Dubot-Poitelon, Pauline Rottier, Justine Lequesne, George Emile
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted
Externí odkaz:
https://doaj.org/article/729e7bcb52cf4560a57a3e58bf74b4ff
Autor:
Antoine Vasseur, Matthieu Carton, Severine Guiu, Paule Augereau, Lionel Uwer, Marie-Ange Mouret-Reynier, Christelle Levy, Jean-Christophe Eymard, Jean-Marc Ferrero, Marianne Leheurteur, Anthony Goncalves, Marie Robert, Thibault De La Motte Rouge, Thomas Bachelot, Thierry Petit, Marc Debled, Thomas Grinda, Isabelle Desmoulins, Laurence Vanlemmens, Vincent Nicolaï, Gaëtane Simon, Luc Cabel
Publikováno v:
Breast, Vol 65, Iss , Pp 136-144 (2022)
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant se
Externí odkaz:
https://doaj.org/article/3e5e3d1b6d254f9091fd5376422aa2e4